Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation
Open Access
- 8 May 2022
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (8) , 485.e1-485.e6
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (P01 CA23766)
- Janssen Pharmaceutica
- National Cancer Institute (P30 CA008748)
- Angiocrine Bioscience
- Amgen
- Omeros Corporation
- Johnson and Johnson
- Takeda Pharmaceuticals U.S.A.
- Spectrum Pharmaceuticals
This publication has 24 references indexed in Scilit:
- Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01Journal of Clinical Oncology, 2012
- Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEMComputer Methods and Programs in Biomedicine, 2011
- Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma GroupBlood, 2008
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTBlood, 2005
- Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphomaBlood, 2004
- High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From the Randomized European CUP TrialJournal of Clinical Oncology, 2003
- G‐CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma and lymphomaBritish Journal of Haematology, 1996
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995
- Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialThe Lancet, 1993
- High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's LymphomaNew England Journal of Medicine, 1987